Enochian Biosciences enters $20M equity purchase agreement with Lincoln Park Capital

Lunai Bioworks Inc.

Up to $20M of common stock may be sold to Lincoln Park over 36 months under a purchase agreement.
Commitment fee of 696,021 shares issued to Lincoln Park upon signing.
Regular purchases up to 30,000 shares per day, with higher limits if stock price thresholds met.
Company can also require accelerated purchases up to 3x regular amount subject to volume.
Proceeds expected for working capital and general corporate purposes.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lunai Bioworks Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to Twenty Million Dollars ($20,000,000) (effective 2023-06-20).

Action: entry
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Value: up to Twenty Million Dollars ($20,000,000)
Effective: 2023-06-20

Exact text from the filing

Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-23-001210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.